secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-017082
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences extends maturity of Adjuvant convertible notes by six months
-------------------------------------------------------------------------------

- Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.
- Notes now due six months after April 10, 2026 (approx. Oct 10, 2026), or upon change of control or acceleration.
- No prepayment of notes allowed before that six-month date without Adjuvant's prior written consent.
- Amendment updates maturity definition in Section 3.1 of the Purchase Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-017082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer